Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice

Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types of hematological malignancies, but have shown limited efficacy in patients with glioblastoma (GBM) or other solid tumors. This may be largely due to the immunosuppressive tumor microenvironment (TME) that compromises CAR-T cells’ delivery and antitumor activity. We previously showed that blocking vascular endothelial growth factor (VEGF) signaling can normalize tumor vessels in murine and human tumors, including GBM, breast, liver, and rectal carcinomas. Moreover, we demonstrated that vascular normalization can improve the delivery of CD8+ T cells and the efficacy of immunotherapy in breast cancer models in mice. In fact, the US FDA (Food and drug administration) has approved seven different combinations of anti-VEGF drugs and immune checkpoint blockers for liver, kidney, lung and endometrial cancers in the past 3 years. Here, we tested the hypothesis that anti-VEGF therapy can improve the delivery and efficacy of CAR-T cells in immunocompetent mice bearing orthotopic GBM tumors. We engineered two syngeneic mouse GBM cell lines (CT2A and GSC005) to express EGFRvIII—one of the most common neoantigens in human GBM—and CAR T cells to recognize EGFRvIII. We found that treatment with the anti-mouse VEGF antibody (B20) improved CAR-T cell infiltration and distribution throughout the GBM TME, delayed tumor growth, and prolonged survival of GBM-bearing mice compared with EGFRvIII-CAR-T cell therapy alone. Our findings provide compelling data and a rationale for clinical evaluation of anti-VEGF agents with CAR T cells for GBM patients.

[1]  C. June,et al.  Next-Generation CAR T-cell Therapies. , 2022, Cancer discovery.

[2]  A. Griffioen,et al.  Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. , 2022, Biochimica et biophysica acta. Reviews on cancer.

[3]  S. Berger,et al.  An NK-like CAR T cell transition in CAR T cell dysfunction , 2021, Cell.

[4]  G. Coukos,et al.  VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding , 2021, Journal for ImmunoTherapy of Cancer.

[5]  R. Jain,et al.  Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas , 2021, Nature Communications.

[6]  V. Dutoit,et al.  Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma , 2021, Frontiers in Immunology.

[7]  Christopher A. Miller,et al.  Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine. , 2020, Neuro-oncology.

[8]  R. Brentjens,et al.  Engineering strategies to overcome the current roadblocks in CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[9]  D. Irvine,et al.  Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor , 2019, Science.

[10]  R. Jain,et al.  Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. , 2019, Annual review of physiology.

[11]  Giles W. Robinson,et al.  Challenges to curing primary brain tumours , 2019, Nature Reviews Clinical Oncology.

[12]  Tracy T Batchelor,et al.  Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium , 2018, Nature Biomedical Engineering.

[13]  R. Martuza,et al.  Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. , 2018, Immunotherapy.

[14]  Dai Fukumura,et al.  Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.

[15]  M. Cilli,et al.  Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model , 2018, Oncoimmunology.

[16]  R. Martuza,et al.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.

[17]  Daniel G. Anderson,et al.  Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy , 2017, The Journal of clinical investigation.

[18]  K. Mansfield,et al.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.

[19]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[20]  Jennie W. Taylor,et al.  Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival , 2016 .

[21]  R. Jain,et al.  Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. , 2016, Journal of the National Cancer Institute.

[22]  Na Li,et al.  Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.

[23]  R. Jain Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.

[24]  R. Jain,et al.  Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.

[25]  P. Maffia,et al.  A novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo. , 2012, Blood.

[26]  S. Rosenberg,et al.  Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.

[27]  T. Seyfried,et al.  Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2–Deficient Mouse Astrocytoma , 2008, Clinical Cancer Research.